三阴性乳腺癌：肿瘤免疫原性及其他

IF 1.6 Q4 ONCOLOGY

International Journal of Breast Cancer Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI:10.1155/2024/2097920

Elio Ibrahim, Ernest Diab, Rony Hayek, Karim Hoyek, Hampig Kourie

{"title":"三阴性乳腺癌：肿瘤免疫原性及其他","authors":"Elio Ibrahim, Ernest Diab, Rony Hayek, Karim Hoyek, Hampig Kourie","doi":"10.1155/2024/2097920","DOIUrl":null,"url":null,"abstract":"Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"2097920"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469932/pdf/","citationCount":"0","resultStr":"{\"title\":\"Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond.\",\"authors\":\"Elio Ibrahim, Ernest Diab, Rony Hayek, Karim Hoyek, Hampig Kourie\",\"doi\":\"10.1155/2024/2097920\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.\",\"PeriodicalId\":46159,\"journal\":{\"name\":\"International Journal of Breast Cancer\",\"volume\":\"2024 \",\"pages\":\"2097920\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469932/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Breast Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/2097920\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/2097920","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

三阴性乳腺癌（TNBC）是一种预后不良、治疗方案有限的乳腺恶性肿瘤。许多研究表明，TNBC 在临床、组织病理学和分子水平上表现出异质性。在这篇综述中，我们将讨论 TNBC 的免疫原性特征，重点是新辅助治疗、辅助治疗和转移性治疗中的免疫疗法和现行治疗标准。此外，我们还讨论了免疫疗法、抗体药物共轭物 (ADC)、多聚 ADP 核糖聚合酶 (PARP) 抑制剂等方面正在进行的研究，以及治疗该疾病的未来挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond.

Triple-negative breast cancer (TNBC) is a breast malignancy with a poor prognosis and limited therapeutic options. Many studies show that TNBC exhibits heterogeneity across clinical, histopathological, and molecular levels. In this review, we discuss the immunogenic features of TNBC with a focus on immunotherapy and the current standard of care in the neoadjuvant, adjuvant, and metastatic setting. In addition, we address the ongoing research on immunotherapy, antibody-drug conjugates (ADCs), poly ADP-ribose polymerase (PARP) inhibitors, and future challenges in the treatment of this entity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Breast Cancer ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

19 weeks

期刊介绍： International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.